Seattle, WA and Miamisburg, OH – October 3, 2024 – RevealDx and Riverain Technologies, leaders in the detection and characterization of lung nodules, announced the integration of their products, as well as distribution by Riverain in Canada. Both companies will be exhibiting at the CHEST Meeting beginning October 7, 2024.
The RevealDX technology characterizes nodules using a patented Malignancy Similarity Index, or mSI to aid Radiologists with patient follow-up recommendations. Riverain’s ClearRead CT technology first suppresses vascular structure on chest CTs, detects pulmonary nodules, and provides volumetric data for each finding.
“Our ClearRead CT technology improves pulmonary nodule detection and characterization while decreasing reading time. This partnership builds upon these benefits by providing additional information that can improve follow-up recommendations,” said Steve Worrell, CEO of Riverain Technologies.
“We are excited to be integrated with Riverain. The two technologies fit perfectly together, and the resulting clinical workflow is efficient. We are excited to go to market in Canada, which has been expanding their lung cancer screening initiatives,” said Chris Wood, CEO of RevealDx.
For more information, contact sales@riveraintech.com.
About RevealDx
RevealDx has developed RevealAI-Lung, the world’s first CADx software for the characterization of lung nodules to receive the CE Mark and Health Canada Approval. The company has published several studies demonstrating significant improvement in both early cancer detection as well as reduction in false positive nodules. Studies show that by integrating this patented technology into routine clinical use, healthcare providers can more effectively triage lung nodules. https://reveal-dx.com/
About Riverain Technologies
Riverain Technologies is on a mission to revolutionize radiology by eliminating delayed cardiothoracic diagnoses. Using a unique suppression technology, ClearRead solutions with Clear Visual Intelligence remove the interfering normal structures within the chest, like bones and vessels, and machine noise, which can compromise accurate and efficient diagnoses. This provides an unimpaired view that enables the radiologist to uniquely focus on the actionable data in chest imaging to precisely detect, characterize, and report findings to improve diagnostic accuracy and advance earlier intervention. For more information: https://www.riveraintech.com/.